Breaking Down Y-mAbs Therapeutics, Inc. (YMAB) Financial Health: Key Insights for Investors

Are you keeping a close watch on Y-mAbs Therapeutics, Inc. (YMAB) and trying to decipher its financial standing? Did you know that in 2024, Y-mAbs reported total revenues of $87.7 million, marking a 3% increase from the previous year? But what does this mean for its overall financial health, especially with a net loss of $6.8 million in Q4 2024? With cash and cash equivalents at $67.2 million as of December 31, 2024, and a strategic focus on radioimmunotherapy, let's delve deeper into the key insights that can help you make informed investment decisions.

Y-mAbs Therapeutics, Inc. (YMAB) Revenue Analysis

Understanding Y-mAbs Therapeutics, Inc. (YMAB)'s financial health requires a close look at its revenue streams. The company focuses on developing and commercializing novel radioimmunotherapy and antibody-based therapeutic products for treating cancer Breaking Down Y-mAbs Therapeutics, Inc. (YMAB) Financial Health: Key Insights for Investors.

Here's a breakdown of Y-mAbs's revenue streams:

• Primary Revenue Sources: The company generates revenue primarily through the sales of its therapeutic products, with DANYELZA being a key contributor. Additionally, Y-mAbs earns revenue from licensing agreements and strategic partnerships.
• Year-over-Year Revenue Growth: Y-mAbs has demonstrated revenue growth over the past few years. For the year 2024, the company's revenue reached $87.7 million, marking a 3% increase compared to the $84.8 million in 2023.
• Historical Revenue Trends:
  • 2024: $87.7 million (3% increase)
  • 2023: $84.8 million (29.96% increase)
  • 2022: $65.26 million (87.03% increase)
  • 2021: $34.89 million (68.18% increase)
  • 2020: $20.75 million
• Contribution of Business Segments: In January 2025, Y-mAbs established two business units: one for the Radiopharmaceuticals Platform and another for DANYELZA commercialization, aiming to optimize the commercial potential of DANYELZA and accelerate the clinical development of its Radiopharmaceuticals Platform.
• Analysis of Changes in Revenue Streams: In Q4 2024, Y-mAbs's total revenues were $26.5 million, a 13% increase year-over-year. This growth was primarily driven by a $2.0 million increase in license revenue and a $1.1 million increase in net product revenues. While U.S. DANYELZA revenues saw a slight decline of 3% for the full year 2024, international DANYELZA revenues grew by 16%.

Here is a table summarizing Y-mAbs's revenue history:

As of December 31, 2024, Y-mAbs had approximately $67.2 million in cash and cash equivalents. The company's total annual cash investment in 2024 was $11.4 million, which was favorable compared to the company's guidance of between $15 million and $20 million.

For the year ended December 31, 2024, Y-mAbs reported a net loss of $29.7 million, or ($0.67) per basic and diluted share. The company anticipates total revenues between $75 million and $90 million for the full year 2025.

Y-mAbs Therapeutics, Inc. (YMAB) Profitability Metrics

Assessing the profitability of Y-mAbs Therapeutics, Inc. (YMAB) requires a detailed examination of several key financial metrics. These include gross profit, operating profit, and net profit margins, which together paint a picture of the company's financial health and operational efficiency. By analyzing these metrics, investors can gain insights into Y-mAbs' ability to generate profits from its revenue, manage its expenses, and ultimately deliver value to its shareholders.

Understanding the trends in these profitability ratios over time is crucial. It helps in identifying whether the company's performance is improving, declining, or remaining stable. Comparing these ratios with industry averages provides a benchmark to determine how well Y-mAbs is performing relative to its peers. This comparative analysis is essential for investors looking to make informed decisions.

Operational efficiency is another critical aspect of profitability. Effective cost management and favorable gross margin trends are indicators of a company's ability to control expenses and maximize revenue. Analyzing these factors can reveal whether Y-mAbs is effectively managing its resources and optimizing its operations to achieve sustainable profitability.

Here's a closer look at some of the specific profitability metrics for Y-mAbs:

• Gross Profit: This is the revenue remaining after deducting the cost of goods sold (COGS). It indicates how efficiently a company manages its production costs.
• Operating Profit: This is the profit earned from a company's core business operations, calculated as revenue less operating expenses (including COGS, salaries, and administrative costs).
• Net Profit: This is the profit remaining after all expenses, including interest and taxes, have been deducted from revenue. It represents the company's bottom-line profitability.
• Profit Margins: These are ratios that measure profitability as a percentage of revenue. Key margins include gross profit margin (gross profit/revenue), operating profit margin (operating profit/revenue), and net profit margin (net profit/revenue).

For the fiscal year 2024, Y-mAbs Therapeutics, Inc. reported the following key financial figures:

Based on the 2024 data, Y-mAbs' financial performance reveals both strengths and areas of concern. The company's gross profit of $55.4 million indicates a strong ability to generate profit from its revenue after deducting the cost of goods sold. However, the operating loss of $(86.0) million and net loss of $(83.8) million highlight significant challenges in managing operating expenses and achieving overall profitability.

Here are some key insights based on the available data:

• Gross Margin: Y-mAbs boasts a high gross margin, calculated as ($55.4 million / $63.3 million) 100, resulting in approximately 87.5%. This suggests efficient management of production costs relative to revenue.
• Operating Expenses: The substantial operating expenses of $141.4 million significantly impact the company's overall profitability, leading to an operating loss.
• Net Loss: The net loss of $(83.8) million indicates that, after accounting for all expenses, Y-mAbs is not currently profitable.

A deeper dive into Y-mAbs Therapeutics, Inc. (YMAB) can be found here: Exploring Y-mAbs Therapeutics, Inc. (YMAB) Investor Profile: Who’s Buying and Why?

Y-mAbs Therapeutics, Inc. (YMAB) Debt vs. Equity Structure

Understanding how Y-mAbs Therapeutics, Inc. (YMAB) finances its operations and growth is crucial for investors. This involves examining the company's debt levels, its debt-to-equity ratio, and how it strategically uses debt and equity to fund its activities.

As of December 31, 2023, Y-mAbs Therapeutics, Inc. (YMAB) reported the following debt details:

• Total Long-Term Debt: $28.748 million

Y-mAbs Therapeutics, Inc. (YMAB) primarily relies on equity to fund its operations. The company's approach to balancing debt and equity can be further understood by examining its debt-to-equity ratio.

The debt-to-equity ratio is a financial metric that compares a company's total debt to its shareholder equity. It is used to evaluate a company's financial leverage. As of December 31, 2023, Y-mAbs Therapeutics, Inc. (YMAB) has a debt-to-equity ratio of 0.21. This indicates that Y-mAbs Therapeutics, Inc. (YMAB) uses more equity than debt to finance its assets, which is often seen as a sign of financial stability.

Here’s a snapshot of Y-mAbs Therapeutics, Inc. (YMAB) assets, liabilities, and equity:

Recent activities, such as debt issuances, credit ratings, or refinancing, provide insights into Y-mAbs Therapeutics, Inc. (YMAB)’s financial strategy. Reviewing these actions helps investors understand how the company manages its capital structure and financial obligations. Recent news and financial statements should be monitored to stay informed on these developments.

To gain more insights into the investors of Y-mAbs Therapeutics, Inc. (YMAB), check out: Exploring Y-mAbs Therapeutics, Inc. (YMAB) Investor Profile: Who’s Buying and Why?

Y-mAbs Therapeutics, Inc. (YMAB) Liquidity and Solvency

Liquidity and solvency are critical indicators of a company's financial health, revealing its ability to meet short-term obligations and sustain long-term operations. For Y-mAbs Therapeutics, Inc. (YMAB), assessing these metrics provides valuable insights into its financial stability and risk profile.

Assessing Y-mAbs Therapeutics, Inc.'s Liquidity:

Analyzing Y-mAbs Therapeutics, Inc.'s liquidity involves examining several key ratios and financial statements to gauge its ability to cover its immediate liabilities.

• Current and Quick Ratios: These ratios measure a company's ability to pay off short-term liabilities with its current assets. The current ratio is calculated by dividing current assets by current liabilities, while the quick ratio excludes inventory from current assets to provide a more conservative measure.
• Analysis of Working Capital Trends: Monitoring the trend of a company's working capital (current assets minus current liabilities) can reveal whether its short-term financial health is improving or deteriorating. A positive and increasing working capital balance generally indicates a company is becoming more liquid.
• Cash Flow Statements Overview: A review of the cash flow statements, specifically focusing on cash flow from operating, investing, and financing activities, provides a comprehensive understanding of how a company generates and uses cash.

Y-mAbs Therapeutics, Inc. (YMAB) reported its financial results for the year 2024. Here’s an overview of their cash flow activities:

• Cash flow from operating activities: For the year 2024, Y-mAbs used $93.3 million in operating activities. This reflects the cash used in the company's core business operations.
• Cash flow from investing activities: In 2024, Y-mAbs's investing activities provided $57.9 million. This suggests the company sold some investments, bringing in cash.
• Cash flow from financing activities: Financing activities used $1.7 million in 2024. This indicates the company was primarily engaged in repaying financing obligations.

The consolidated balance sheets provide a snapshot of the company's assets, liabilities, and equity as of December 31, 2024, and December 31, 2023. Here are some key figures:

• Cash and Cash Equivalents: As of December 31, 2024, Y-mAbs had $67.2 million in cash and cash equivalents, compared to $104.8 million at the end of 2023.
• Marketable Securities: The company held $46.7 million in marketable securities as of December 31, 2024, down from $67.2 million in the previous year.
• Total Assets: Total assets amounted to $139.8 million as of December 31, 2024, a decrease from $184.9 million in 2023.
• Total Liabilities: Total liabilities were $41.7 million as of December 31, 2024, slightly up from $41.1 million in 2023.
• Stockholders’ Equity: Stockholders' equity stood at $98.1 million as of December 31, 2024, a decrease from $143.8 million in 2023.

The decrease in cash and cash equivalents, marketable securities, and total assets, coupled with a net loss, indicates potential liquidity challenges. Investors should monitor these trends closely, especially the burn rate of cash, to assess the company's ability to fund its operations and investments in the near term.

For more insights into Y-mAbs Therapeutics, Inc. (YMAB), consider reading: Exploring Y-mAbs Therapeutics, Inc. (YMAB) Investor Profile: Who’s Buying and Why?

Y-mAbs Therapeutics, Inc. (YMAB) Valuation Analysis

Assessing whether Y-mAbs Therapeutics, Inc. (YMAB) is overvalued or undervalued requires a multifaceted approach, incorporating key financial ratios, stock performance analysis, and analyst opinions. These elements, when combined, offer a comprehensive view of the company's valuation.

To determine if Y-mAbs Therapeutics, Inc. (YMAB) is overvalued or undervalued, consider the following:

• Price-to-earnings (P/E) Ratio: This ratio compares the company's stock price to its earnings per share. As of now, Y-mAbs Therapeutics, Inc. (YMAB) does not have a P/E ratio because its earnings per share are negative (-$2.81). A high P/E ratio suggests overvaluation, while a low one may indicate undervaluation.
• Price-to-book (P/B) Ratio: The P/B ratio compares a company's market capitalization to its book value of equity. As of the latest data, Y-mAbs Therapeutics, Inc. (YMAB) has a Price to Book ratio of 2.83. Generally, a lower P/B ratio could imply undervaluation, while a higher ratio might suggest overvaluation.
• Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: This ratio compares a company's enterprise value to its earnings before interest, taxes, depreciation, and amortization. As of the latest information, Y-mAbs Therapeutics, Inc. (YMAB) has an EV/EBITDA ratio of -13.87. A lower ratio might indicate undervaluation, while a higher one could suggest overvaluation.

Analyzing stock price trends provides additional insights into market sentiment and valuation perceptions. Over the past year, Y-mAbs Therapeutics, Inc. (YMAB) stock has shown considerable volatility. As of April 2025, the stock price is $14.06. Recent stock performance reveals:

Y-mAbs Therapeutics, Inc. (YMAB) does not currently offer a dividend, so dividend yield and payout ratios are not applicable.

Analyst consensus is a crucial factor in valuation assessment. Recent ratings indicate:

Based on 4 analysts offering 12-month price targets for Y-mAbs Therapeutics, Inc. (YMAB) in the last 3 months, the average price target is $25.50, with a high estimate of $40.00 and a low estimate of $17.00. The current price of $14.06 suggests a potential upside.

Here's a summary of analyst ratings:

These ratings reflect the analysts' consensus on whether the stock is likely to increase in value (buy), remain stable (hold), or decrease in value (sell).

For further insights into Y-mAbs Therapeutics, Inc. (YMAB) financial health, you can read more here: Breaking Down Y-mAbs Therapeutics, Inc. (YMAB) Financial Health: Key Insights for Investors

Y-mAbs Therapeutics, Inc. (YMAB) Risk Factors

Y-mAbs Therapeutics, Inc. (YMAB) faces a variety of risks that could significantly impact its financial health. These risks span internal operational challenges and external market dynamics, each requiring careful consideration by investors.

Internal and External Risks:

• Industry Competition: The biotechnology industry is intensely competitive. Y-mAbs faces competition from larger, more established pharmaceutical companies with greater resources. These competitors may develop and market products that are more effective or less expensive, which could reduce the demand for Y-mAbs' products.
• Regulatory Changes: The development, approval, and marketing of Y-mAbs' products are subject to extensive regulation by governmental authorities in the United States and other countries. Changes in these regulations, such as stricter approval requirements or new safety data, could delay or prevent the approval of Y-mAbs' products, increase the costs of development, or limit the commercial potential of approved products.
• Market Conditions: Economic downturns, changes in healthcare policies, and shifts in market preferences can all impact the demand for Y-mAbs' products. For example, reduced healthcare spending or increased pressure on pricing could negatively affect the company's revenues and profitability.

Operational, Financial, and Strategic Risks:

Recent earnings reports and filings highlight several key risks:

• Clinical Trial Risks: Y-mAbs' pipeline depends heavily on the success of its clinical trials. Delays, failures, or inconclusive results in these trials could halt the development of key product candidates and significantly harm the company's prospects.
• Manufacturing Risks: Manufacturing complex biologic products is challenging. Y-mAbs relies on third-party manufacturers, and any disruptions in their operations, quality control issues, or capacity constraints could impact the supply of its products and increase costs.
• Commercialization Risks: Even if Y-mAbs' products are approved, their commercial success is not guaranteed. Factors such as market acceptance, pricing, reimbursement policies, and competition can all affect sales.
• Financial Risks: Y-mAbs needs substantial capital to fund its operations. The company may need to raise additional funds through equity or debt financings, which could dilute existing shareholders or increase its debt burden. As of the fiscal year 2024, Y-mAbs reported a net loss of $90.2 million. Maintaining adequate liquidity and managing cash flow are critical.

Mitigation Strategies:

While specific details of mitigation strategies may vary, Y-mAbs generally employs the following approaches:

• Diversification of Pipeline: Y-mAbs is working to develop a diverse pipeline of product candidates to reduce its reliance on any single product.
• Strategic Partnerships: The company may enter into partnerships with other companies to share the risks and costs of development and commercialization.
• Risk Management Programs: Y-mAbs has implemented risk management programs to identify, assess, and mitigate potential risks.
• Insurance Coverage: The company maintains insurance coverage to protect against certain risks, such as product liability claims.

Understanding these risks and mitigation strategies is crucial for investors assessing Y-mAbs' long-term financial health and potential.

To gain further insights into the values and principles guiding the company, explore Mission Statement, Vision, & Core Values of Y-mAbs Therapeutics, Inc. (YMAB).

Y-mAbs Therapeutics, Inc. (YMAB) Growth Opportunities

Y-mAbs Therapeutics, Inc. (YMAB) faces several key growth drivers that could shape its future performance. These include potential product innovations, strategic market expansions, and possible acquisitions. Evaluating these factors provides insights into the company’s capacity for sustained growth.

Several factors suggest potential revenue growth for Y-mAbs. Analysts estimated that the firm’s revenue for the fiscal year 2024 could reach $59.2 million. Looking ahead, projections for fiscal year 2025 estimate revenues of about $77.97 million. These projections suggest a positive trajectory, reflecting optimism about the company's future performance and market penetration. Breaking Down Y-mAbs Therapeutics, Inc. (YMAB) Financial Health: Key Insights for Investors

Strategic partnerships and initiatives are crucial for Y-mAbs to leverage its existing resources and expand its market reach. While specific partnerships aren't detailed here, such collaborations often involve co-development agreements, licensing deals, or joint ventures that can significantly boost a company's growth prospects.

Y-mAbs aims to leverage several competitive advantages to foster growth:

• Innovative Product Pipeline: Focus on developing novel immunotherapies.
• Strategic Collaborations: Forming partnerships to expand market reach and accelerate development.
• Experienced Leadership: Leveraging expertise to navigate regulatory pathways and commercialization.

Here's a look at the projected financials:

These figures highlight anticipated growth, driven by strategic initiatives and market dynamics.